Global Bleomycin Sulfate Market Size, Share and Trends Analysis Report, By Type (15 Units Vial and 30 Units Vial), By Route of Administration (Intramuscular, Intravenous, Subcutaneous, and Intrapleural), and By Application (Lymphoma Drug, Testicular Cancer Drug, Ovarian Cancer Drug, and Cervical Cancer Drug), Forecast (2022-2028)

The global bleomycin sulphate market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The growth of the market is attributed to the global prevalence of different types of cancer like testicular drug cancer, ovarian cancer, cervical cancer, squamous cell carcinoma and others. According to World Health Organization (WHO), cancer is the biggest cause of mortality globally, with approximately 10 million fatalities expected in 2020, accounting for roughly one in every six deaths. Tobacco use, a high BMI, alcohol use, a low fruit and vegetable intake, and a lack of physical activity account for almost one-third of cancer fatalities. In low- and lower-middle-income nations, cancer-causing diseases such as the human papillomavirus (HPV) and hepatitis account for around 30% of cancer cases. Many tumors can be cured if caught early and appropriately treated.
Additionally, the rising demand for bleomycin sulphate along with the technological advancements and new product launches across the globe is propelling the growth of the global bleomycin sulphate market. For instance, in February 2022, the US Food and Drug Administration (FDA) approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy for the treatment of adult patients with certain types of large B-cell lymphoma for those who have not responded to, at least two other types of systemic treatment. Breyanzi, is the third gene therapy which is approved by the USFDA for different types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Breyanzi is not advised for the treatment of patients having primary central nervous system lymphoma.
For instance, in January 2022, MobileODT announced the launch of the VisualCheck algorithm for identification of cervical cancer. The VisualCheck technology uses different AI algorithms for non-invasive cervical cancer screening. With the use of multiple AI algorithms, VisualCheck provides results in less than 60 seconds, with accuracy similar to that of leading experts. The new technology has been integrated with pathology results as a ground truth, which will aid in recognizing patterns that may not normally be visible to the human eye. Additionally, the algorithm incorporates human-annotated images. The VisualCheck technology closely identifies cervical cancer and pre-cancer distribution in patients.
Some major players in the market include Cipla Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Zhejiang Hisun Pharmaceutical Co. Ltd., among others. The market players are helping significantly in the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, in order to stay in the competition of the market. For instance, in November 2022, the US Food and Drug Administration (FDA) approved Cytalux, an imaging drug which is intended to assist surgeons in identifying ovarian cancer lesions. The drug is made to improve the ability to locate additional ovarian cancerous tissue that is normally difficult to detect at the time of surgery. Cytalux is developed for use in adult patients with ovarian cancer to help identify cancerous lesions during surgery. The drug is a diagnostic agent that is given in the form of an intravenous injection prior to surgery.
For instance, in March 2022, Teva Pharmaceuticals announced the launch of its first generic version of Revlimid in the US, which is a treatment for myelodysplastic syndrome, multiple myeloma, and mantle cell lymphoma. A myelodysplastic syndrome is a group of disorders caused when something disrupts the production of blood cells, multiple myeloma is a cancer that forms in plasma cells, and mantle cell lymphoma is a very rare condition of B cell non-Hodgkin lymphoma. Teva launched the generic version of Revlimid, in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US.

Market Coverage
The market number available for – 2022-2028
Base year- 2022
Forecast period- 2022-2028
Segment Covered-
By Type
By Route of Administration
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Top Major Key Players:
Cipla Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Zhejiang Hisun Pharmaceutical Co. Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Bleomycin Sulphate Market Report by Segment
By Type
15 Units Vial
30 Units Vial
By Route of Administration
Intramuscular
Intravenous
Subcutaneous
Intrapleural
By Application
Lymphoma Drug
Testicular Cancer Drug
Ovarian Cancer Drug
Cervical Cancer Drug